fda approves first oral glp-1 obesity drug august 1 2025 Novo Nordisk's weight-loss pill wins approval FDA Approves First GLP-1 Pill
Description
Tan X, Divino V, Amamoo J, Xie L, Coyle KB, Gamble CL, et al

[Accessed on 18.4.2015]

The study showed that the renal extraction of GLP-1, natriuretic effect of GLP-1 and change of plasma concentrations of ANG II was abolished by the GLP-1 receptor antagonist Exendin 939 (Ex 939), suggesting that GLP-1-induced natriuresis is dependent on GLP-1 receptor activation 38

Common adverse reactions included nausea, diarrhea, and vomiting

Available from: Ethics declarations Conflicts of Interest The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript

Predefined sensitivity analyses to determine potential confounding influence were conducted with the same statistical analysis set-up removing (1) patients with IIH without papilledema (IIH-WOP), and (2) patients with pre-existing migraine
